CytomX Therapeutics (CTMX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
Zacks Investment Research on MSN14h
Veeva (VEEV) Upgraded to Strong Buy: Here's Why
Veeva Systems (VEEV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...
Analysts are showing growing confidence in European and Chinese tech stocks as they outperform the S&P 500 (SPX). Many ...
Quality dividend stocks yielding 7% and more are the best ideas for many investors now. These five are too cheap to ignore ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Quality dividend stocks yielding 7% and more are the best ideas for many investors now. These five are too cheap to ignore any longer. You can follow him investing $500,000 of his own money on our top ...
Despite Q4 earnings hit by transaction costs, CBIZ expects smoother progress and significant growth in 2025. See why I ...
PennantPark (PFLT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
NuScale Power (SMR) stock is down over 30% in the past month, catalyzed by a reported year-over-year rise in net losses from ...